DÜSSELDORF, Germany, Feb. 25, 2020 /PRNewswire/ -- FUJIFILM Europe GmbH will launch a new function known as "CAD EYE," which was developed by FUJIFILM Corporation to support real-time detection of colonic polyps during colonoscopy utilizing AI technology (*1). CAD EYE's functionality will be available with software EW10-EC01 and the compatible expansion unit EX-1 in combination with the Fujifilm ELUXEO 7000 system. Fujifilm has already acquired CE mark for this new software EW10-EC01 and it will be launched with EX-1 in March 2020.
Improving the detection rate of difficult to discover lesions has been one of the major challenges within the field of endoscopy in recent years. Fujifilm has continuously worked on the development of image processing technologies such as Linked Color Imaging (LCI) and Blue Light Imaging (BLI) utilizing specific wavelengths of light to support early cancer detection and characterization.
"I am very pleased to announce the launch of the CAD EYE Detection function. I am convinced that with this new development, we will achieve our vision of reducing the incidence of colorectal cancers and patient mortality whilst lowering the economic burden associated with the management and aftercare that results from this devastating disease," says Mr. Takakazu Sakashita, Senior Vice President FUJIFILM Europe GmbH Medical Systems Division. "CAD EYE utilizes Fujifilm's medical Artificial Intelligence technology REiLI. Fujifilm has a highly capable image processing R&D organisation and through this powerful technological heritage, we have been able to quickly develop new solutions that meet the real needs of our global customers."
"CAD EYE has been trained with a powerful super-computer located in Fujifilm's global AI technology centre in Tokyo, utilising an immense amount of clinical images using Fujifilm endoscopy systems," says Takemasa Kojima, Vice President FUJIFILM Europe GmbH Head of Sales and Marketing Endoscopy System. "This ensures that CAD EYE is a customised detection support compatible with the ELUXEO system. It is user-friendly, simple and intuitive: an excellent and effective support tool during long hours in the examination room aimed to improve lesion detection in the colon at expert level."
CAD EYE Detection is automatically activated when observing with White Light or LCI mode to support real-time lesion detection (*2). A user-friendly interface has been pursued for ease of use and simplicity, which does not interfere with the endoscopic image, and minimises operators' eye movement.
When a suspicious polyp is detected within the endoscopic image, a Detection Box indicates the area where the suspicious polyp has been detected, and a Visual Assist Circle illuminates in the vicinity. Additionally a sound is heard when a suspicious polyp is detected.
For sales inquiries, please contact FUJIFILM's subsidiaries or authorised distributors in each country or region.
Background:
Colorectal cancer is the third most common cancer after lung cancer and breast cancer in terms of the number of cases, and the second most common cause of cancer death after lung cancer (*3). And in order to reduce the incidence of cancer, colonoscopy is widely considered the gold standard for detection of colonic neoplasia. However, errors in colonoscopic detection of neoplasia, including both polyps and cancers, are well documented and improvement of detection rate of such legions has been one of the major topics in the gastroenterology field. (4*, 5*)
Fujifilm is working to develop a unique collection of image processing technologies and continues to develop the practical application of AI technology and will continue to develop and supply a wide range of products and services that meet the needs of frontline medicine in various fields, contributing to streamlining clinical work, enhancing the quality of medical care and maintaining and strengthening people's health.
(1*) Fujifilm's brand name of function to assist computer-aided-diagnosis (CAD) in endoscopy utilising AI technologies
(2*) Detection support function is automatically turned off when observing with BLI (Blue Light Imaging) mode.
(3*) WHO database https://www.who.int/news-room/fact-sheets/detail/cancer
(4*) DOUGLAS K. REX, et al. Colonoscopic Miss Rates of Adenomas Determined by Back-to-Back Colonoscopies, GASTROENTEROLOGY 1997;112:24-28
(5*) Ann G. Zauber, et al. Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths, The NEW ENGLAND JOURNAL of MEDICINE 2012; 366:687-696 DOI: 10.1056/NEJMoa1100370
About FUJIFILM Europe GmbH
FUJIFILM Europe GmbH (Düsseldorf, Germany) acts as strategic headquarter for the region and supports its group companies in Europe by formulating marketing and corporate strategies. Fujifilm entities operate in over 50 group companies and branches in Europe and employ around 4,500 people engaged in R&D, manufacturing, sales, and service. Throughout Europe they serve a range of industries including medical technology, graphic systems, electronic materials, chemicals, optical devices, recording media, and photography. Over the last decade, the company has more intensively focused on healthcare, and now looks back on over 80 years of experience in medical imaging. Today, Fujifilm provides the entire spectrum of patient care, ranging from prevention to diagnostics and therapy solutions. Today, research and development in medicine, bio-pharmaceuticals, as well as regenerative medicine are part of Fujifilm's unique portfolio.
For more information, please visit: www.fujifilm.eu
Photo - https://mma.prnewswire.com/media/1095015/CAD_EYE_AI.jpg
Logo - https://mma.prnewswire.com/media/1095014/CAD_EYE_Logo.jpg
